A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Characteristics of SG301 SC Injection in Single-dose Healthy Subjects and Multiple-dose Systemic Lupus Erythematosus (SLE) Subjects
Latest Information Update: 01 Jul 2025
At a glance
- Drugs SG 301 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Hangzhou Sumgen Biotech
Most Recent Events
- 25 Jun 2025 Planned End Date changed from 24 Oct 2025 to 24 Oct 2026.
- 25 Jun 2025 Planned primary completion date changed from 19 May 2025 to 19 May 2026.
- 27 Nov 2023 New trial record